Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
Author:
Affiliation:
1. Department of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, CA; and
2. Section of Experimental Haematology, Cancer Division, University of Glasgow, Glasgow, United Kingdom
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/111/4/2329/1221698/zh800408002329.pdf
Reference29 articles.
1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.;Druker;N Engl J Med,2006
2. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.;Gorre;Science,2001
3. Active transport of imatinib into and out of cells: implications for drug resistance.;Thomas;Blood,2004
4. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.;Dai;J Biol Chem,2004
5. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.;Donato;Cancer Res,2004
Cited by 91 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-01
2. Prospective pharmacological potential of cryptotanshinone in cancer therapy;Pharmacological Research - Modern Chinese Medicine;2023-12
3. Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia;Cancers;2023-02-03
4. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms;International Journal of Molecular Sciences;2021-01-11
5. STAT3 and p53: Dual Target for Cancer Therapy;Biomedicines;2020-12-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3